

Magle Chemoswed appoints new Chief Strategy Officer

Magle Chemoswed Holding is pleased to announce the appointment of Simon Jegou as Chief Strategy Officer of the Magle Chemoswed Holding Group.

Simon will join in January 2022 and report to CEO Justin Pierce. He will be responsible for driving the company's strategic goals and support in future value creation by identifying growth opportunities.

A seasoned life-science industry leader, Simon has held various senior roles before joining Magle Chemoswed, most recently as Head of Business Development at LU Innovation in Lund, Sweden. Across his career, he has led teams through strategic product development and worked with developing and implementing strategic objectives. In addition, Simon has experience as a leader and board member in various companies and brings a wealth of knowledge and an extensive network in the European life science industry.

Justin Pierce, the CEO of Magle Chemoswed, said, "Simon's wealth of industry experience is going to be a real asset to Magle Chemoswed. He truly values the importance of strategic development and will be instrumental in converting our strategic potential into company value for all stakeholders. I am thrilled to welcome Simon to the team, and I look forward to us working closely together as we continue to grow our brand and technology platform."

Simon Jegou commented, "I am really excited to embark on this new journey with Magle Chemoswed and bring my experience to help the company seize new growth opportunities and develop innovative solutions that better serve both customers and patients."

Contacts

Justin Pierce, CEO, phone +46 (0)70 593 58 21, justin.pierce@maglechemoswed.com

About Us

Magle Chemoswed is a unique international contract development manufacturing company dedicated to bringing ideas to product for customers alongside building our own product pipeline based on our patented technology base. As an integrated company, we have extensive capabilities across the value chain, from the discovery, development and manufacture of medicines and medical devices that rely on our patented and trade secret protected technology platform.

Västra Hamnen Corporate Finance is the Company's certified advisor on Nasdaq First North Growth Market and can be reached at ca@vhcorp.se or +46 (0) 40 200 250.

Attachments

[Magle Chemoswed appoints new Chief Strategy Officer](#)

